Toggle light / dark theme

Researchers remain perplexed as to why some patients infected with SARS-CoV-2, the virus responsible for COVID-19, remain asymptomatic while other patients develop severe disease symptoms. This question is once again at the front of mind as the Delta variant spreads across the country. In a new retrospective study, researchers at the Medical University of South Carolina (MUSC) discovered a specific and sensitive biomarker in blood samples that predicts which patients will develop COVID-19 symptoms. Their results, published online on July 9 in Scientific Reports, show that reduced levels of a specific lipid, sphingosine, are significantly associated with developing COVID-19 symptoms. Conversely, elevated levels of sphingosine, as well as a protein involved in its production, acid ceramidase (AC), are associated with asymptomatic infections.

“We developed this project at a time when there wasn’t a successful vaccine,” said Besim Ogretmen, Ph.D., director of the Lipidomics Shared Resource at Hollings Cancer Center and leader of the Hollings Developmental Cancer Therapeutics Research Program. “We wanted to contribute to the field and know which patients who were exposed to this virus would be symptomatic versus asymptomatic.”

Over the past 16 months several waves of SARS-CoV-2 infections in the U.S. have resulted in more than 35 million cases and almost 630000 deaths. Despite the development of multiple safe and effective vaccines, we are currently experiencing another wave of infections.

Researchers have discovered one of the oldest and best-preserved brains in the fossil record. A 310-million-year-old horseshoe crab was found with its complete brain intact, thanks to a previously unknown preservation method.

The majority of our knowledge of ancient creatures comes from bones – soft tissues don’t fossilize very well. Some mechanisms are better than others at preserving these fragile tissues though, most famously amber. Scientists can then scan amber-encased creatures to image their brains and other organs.

But that record only goes back so far. The oldest amber inclusions date back about 230 million years ago, to the Triassic period. Burgess Shale-type deposits, however, extend as far back as 520 million years ago, to the early Cambrian. These mudstone deposits can also preserve soft tissues as carbon films – most commonly the gut, but on rare occasions imprints of parts of the nervous system can be found.

Upon an otherwise unruly landscape of choppy sea and craggy peaks, the salmon farms that dot many of Norway’s remote fjords impose a neat geometry. The circular pens are placid on the surface, but hold thousands of churning fish, separated by only a net from their wild counterparts. And that is precisely the conundrum. Although the pens help ensure the salmon’s welfare by mimicking the fish’s natural habitat, they also sometimes allow fish to escape, a problem for both the farm and the environment.

In an attempt to prevent escaped fish from interbreeding with their wild counterparts and threatening the latter’s genetic diversity, molecular biologist Anna Wargelius and her team at the Institute of Marine Research in Norway have spent years working on ways to induce sterility in Atlantic salmon. Farmed salmon that cannot reproduce, after all, pose no threat to the gene pool of wild stocks, and Wargelius has successfully developed a technique that uses the gene-editing technology Crispr to prevent the development of the cells that would otherwise generate functioning sex organs.

In fact, Wargelius’ team was a little too successful. To be financially viable, commercial fish farms need at least some of their stock to reproduce. So the scientists went a step further, developing a method of temporarily reversing the modification they had already made. They’ve created what they call “sterile parents.”

As a cardiac electrophysiologist, Deeptankar DeMazumder has worked for years with people at risk for sudden cardiac arrest (SCA). Despite the latest medical advances, less than 10 percent of individuals stricken with an SCA will survive this highly dangerous condition in which irregular heart rhythms, or arrhythmias, cause the heart suddenly to stop beating.

In his role as a physician, DeMazumder keeps a tight focus on the electrical activity in their hearts, doing his best to prevent this potentially fatal event. In his other role, as a scientist at the University of Cincinnati College of Medicine, DeMazumber is also driven by a life-saving aspiration: finding ways to identify at-risk individuals with much greater accuracy than currently possible—and to develop better ways of protecting them from SCAs. He recently received a 2020 NIH Director’s New Innovator Award to pursue one of his promising ideas.

SCAs happen without warning and can cause death within minutes. Poor heart function and abnormal heart rhythms are important risk factors, but it’s not possible today to predict reliably who will have an SCA. However, doctors already routinely capture a wealth of information in electrical signals from the heart using electrocardiograms (ECGs). They also frequently use electroencephalograms (EEGs) to capture electrical activity in the brain.

The mosquito-borne Zika virus is an emerging pathogen from the Flavivirus genus for which there are no approved antivirals or vaccines. Using the clinically validated PDK-53 dengue virus vaccine strain as a backbone, we created a chimeric dengue/Zika virus, VacDZ, as a live attenuated vaccine candidate against Zika virus. VacDZ demonstrates key markers of attenuation: small plaque phenotype, temperature sensitivity, attenuation of neurovirulence in suckling mice, and attenuation of pathogenicity in interferon deficient adult AG129 mice. VacDZ may be administered as a traditional live virus vaccine, or as a DNA-launched vaccine that produces live VacDZ in vivo after delivery. Both vaccine formulations induce a protective immune response against Zika virus in AG129 mice, which includes neutralising antibodies and a strong Th1 response.

Current tissue engineering strategies lack materials that promote angiogenesis. Here the authors develop a microfluidic in vitro model in which chemokine-guided endothelial cell sprouting into a tunable hydrogel is followed by the formation of perfusable lumens to determine the material properties that regulate angiogenesis.

The Israeli inventor of a “precision medicine” for COVID-19 is “very optimistic,” after an 88-person hospital trial entered its final day without a single patient ending up on a ventilator.


Placebo study still to come, but inventor says medication ‘could be a game changer’ after around 9 out of 10 participants in Greek trial are released from hospital within 5 days.

But 2-AG is almost immediately converted to arachidonic acid, a building block for inflammatory compounds called prostaglandins. The researchers showed that the ensuing increase in arachidonic acid levels resulted in the buildup of a particular variety of prostaglandin that causes constriction of tiny blood vessels in the brain where the seizure has induced thatprostaglandin’s production, cutting off oxygen supply to those brain areas.


Summary: The release of 2-AG, a natural endocannabinoid that is suggested to be the brain’s equivalent to THC, dampens down seizure activity but increases post-seizure oxygen deprivation in the brain.

Source: Stanford

A marijuana-like chemical in the brain, mirroring its plant-based counterpart, packs both ups and downs.

Epileptic seizures trigger the rapid synthesis and release of a substance mimicked by marijuana’s most psychoactive component, Stanford University School of Medicine investigators have learned. This substance is called 2-arachidonoylglycerol, or 2-AG, and has the beneficial effect of damping down seizure intensity.